Memphasys Completes $579K Placement, Total Funds Raised Surpass $1.12M
Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.
- Placement of 193 million shares at $0.003 each raising $579K
- Total funds raised under Prospectus now exceed $1.12 million
- 48 million free attaching unlisted options issued
- Funds to accelerate Felix™ System sales in Europe and MENA
- Focus on regulatory approvals in Australia and India
Capital Raising Completes Shortfall Offer
Memphasys Limited (ASX – MEM), an Australian reproductive biotechnology company, has successfully completed the placement of 193,055,540 new shares at an issue price of $0.003 per share. This shortfall placement raises approximately $579,167, bringing the total capital raised under its recent entitlement offer prospectus to over $1.12 million. Alongside the shares, the company issued 48,263,886 free attaching unlisted options exercisable at $0.011 each before November 2026.
Backing Commercial Momentum for Felix™ System
The capital injection comes at a pivotal time for Memphasys, which recently secured CE Mark approval for its flagship Felix™ System. This regulatory milestone unlocks immediate market access across Europe, enabling the company to accelerate direct sales and commercial execution. The company has also inked a long-term commercial agreement with Centro Fertilità Assistita (CFA) Italia, further validating its commercial prospects.
Strategic Use of Funds
Memphasys plans to deploy the proceeds primarily to expand sales efforts across Europe and the Middle East and North Africa (MENA) region, with particular emphasis on markets like Qatar where CE approval permits immediate sales. Additionally, the funds will support manufacturing scale-up, inventory build, and margin optimisation to meet early commercial demand. The company is also prioritising regulatory approvals in Australia and India, aiming to unlock further high-value markets.
Outlook and Market Positioning
By combining electrophoresis and size-exclusion membranes, the Felix™ System offers a gentler, faster, and more standardised sperm selection process compared to traditional methods. Memphasys is positioning Felix™ as a new global standard in assisted reproductive technology, leveraging its patented technology to improve clinical outcomes. The recent capital raise strengthens the company’s balance sheet, enabling it to capitalise on regulatory and commercial momentum and scale its operations effectively.
Next Steps
The new shares and options were issued on 30 December 2025, with related ASX filings to follow. Investors will be watching closely for updates on sales traction in Europe and MENA, progress on regulatory approvals in Australia and India, and the company’s ability to scale manufacturing and optimise margins in the coming months.
Bottom Line?
Memphasys’ latest capital raise sets the stage for accelerated commercial growth, but regulatory timelines remain a key watchpoint.
Questions in the middle?
- How quickly will regulatory approvals in Australia and India be secured?
- What early sales traction can Memphasys demonstrate in Europe and MENA?
- How effectively can the company scale manufacturing to meet demand?
